The effect of anifrolumab on cutaneous lupus erythematosus characterized by the change of the inflammatory infiltrate analyzed by immunohistochemistry, spatial transcriptomics and single-cell RNA- and TCR-sequencing as well as on the clinical outcome - an open label, single arm phase IV pilot study
Latest Information Update: 19 Feb 2026
At a glance
- Drugs Anifrolumab (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Therapeutic Use
Most Recent Events
- 19 Feb 2026 New trial record